February 2, 2022 4:48pm

As I had stated this a.m., “a foreshadowing of a storm of algorithms – wait, wait for the “rules” that weaken”

Pre-open Indications: 5 Hits and 3 Miss

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares down -$0.53 with 502 shares traded after Tuesday’s +$0.40 with 1,088 shares after Monday’s 11 shares traded.

If I have learned one thing as a former research analyst, venture and public fund investor then a journalist; it is that your life and your bank account are largely tied to your questioning of price movements and targets.

Who else is tracking a broad grouping of cell and gene therapy equities – with facts supported by real numbers?

The Dow closed UP +212.89 points (+0.60%); the S&P closed UP +42.77 points (+0.94%) while the Nasdaq closed UP +71.54 points (+0.50%)

 

Henry’omics:

Indexes rose for a fourth (4th) straight day Tuesday, as tech earnings came out strong.

Economic Data Docket: private payroll data fell by 301,000 for the month of January, which was down from December’s growth of 807,000 private payrolls, ADP reported. Economists were expecting 200,000 private jobs were added in January.

  • Friday’s payrolls report to show a decline of 400,000 while Goldman Sachs is forecasting a drop of 250,000. Consensus forecast is for a gain of 150,000.

 

RegMed Investors’ (RMi) pre-open: “spinning or tilting? A very weak aftermarket, a foreshadowing of a storm of algorithms – wait, wait for the “rules” that weaken” …  https://www.regmedinvestors.com/articles/12282

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Wednesday opened negative at 4 up/30 downs and 1 acquired, stayed negative at the mid-day at 2/32 and 1 acquired, ending with a negative close of 1/33 and 1 acquired;

 

Pre-open indications: 4 Hits < Sell into Strength:  Applied Genetic Technologies (AGTC -$0.06), BioLife Solutions (BLFS -$1.03), Biostage BSTG -$0.53), Fate Therapeutics (FATE -$1.52)> 4 MISS < Alnylam Pharmaceuticals (ALNY +$0.23), BUY: CRISPR Therapeutics (CRSP -$3.41), Editas Medicine (EDIT -$1.47), Intellia Therapeutics (NTLA -$4.41)   

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares down -$0.53 with 502 shares traded after Tuesday’s +$0.40 with 1,088 shares after Monday’s 11 shares traded after Friday’s +$0.05 with 3,225 shares traded after Thursday’s +$0.24 with 10,073 - double the mornings 5,030 shares traded after last Wednesday’s diving to -$0.00 with 7,796 shares trading after appreciating +$0.35 (after dropping mid-day -$0.07 – such sarcasm after miraculous jump) and the previous Tuesday’s +$0.31 with 2,794 shares traded.

 

Key Metrics:

  • Wednesday - Sector volume was LOW with 1 of the 1-upside having higher than the 3-month average volume with LOW volume of 9 of 32-downside having higher than the 3-month average volume

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday the IBB closed down -0.95% and XBI closed down -3.36%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was up +0.13 points or +0.59% at 22.09

 

Jumping with share pricing momentum (1 of 1):

  • Alnylam Pharmaceuticals (ALNY +$0.33 after Tuesday’s +$7.33 and Monday’s +$5.51),

Hammered in today’s market (10 of 33):

  • Intellia Therapeutics (NTLA -$4.41 after Tuesday’s +$5.23 and Monday’s +$8.55),
  • CRISPR Therapeutics (CRSP -$3.41 after Tuesday’s +$1.78 and Monday’s +$4.75),
  • Ultragenyx (RARE -$2.13 after Tuesday’s +$2.11 and Monday’s +$3.93),
  • ReNeuron (RENE.L -$2.90 after Tuesday’s +$0.50 and Monday’s -$0.50),
  • Regenxbio (RGNX -$1.95 after Tuesday’s +$0.43),
  • Vericel (VCEL -$1.57),
  • Fate Therapeutics (FATE -$1.52 after Tuesday’s -$0.40 and Monday’s +$4.88),
  • Editas Medicine (EDIT -$1.47 after Tuesday’s +$0.65 and Monday’s +$1.61),
  • Global Blood Therapeutics (GBT -$1.23 after Tuesday’s +$0.48 and Monday’s +$1.43),
  • BioLife Solutions (BLFS -$1.03 after Tuesday’s +$0.54 and Monday’s +$2.34),

Closing Flat:

  • 1 - Stemline Therapeutics (STML) – acquired

 

February, Q1/2022:

  • Wednesday closed negative with 1 incliners, 33 decliners and 1 acquired
  • Tuesday closed positive with 26 incliners, 7 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: As I stated yesterday, “Are we here for the money or the losses? I keep saying SELL at the highs so one can come back as bottoms emerge after Q4 and FY21 numbers resound.”

I learned very early (military), if you weren’t 5 minutes early for a meeting, you were 10 minutes late – be early in portfolio deliberations

Q4 and end-of-year earnings are about to be made aware of” more than even I thought.

  • Alnylam Pharmaceuticals (ALNY) reports Q4 and FY21 on Thursday, 2/10
  • AxoGen AXGN) – 2/22, Tuesday

Algorithms, hedge funds and traders continue to punish and … then push the cell and gene therapy stocks as valuations “creep” up.

  • Early January 2022 has delivered fewer gains but also generated algorithmic based losses.

WHY do I keep analyzing Biostage (BSTG): I WAS there to experience the harassment and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.